AestheFill艾塑菲聚乳酸面部填充剂

Search documents
争夺艾塑菲中国代理权,谁更需要“童颜针”
Jing Ji Guan Cha Wang· 2025-07-26 01:59
Core Viewpoint - The announcement from Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (ST Wuzhong) regarding the termination of the exclusive distribution agreement for AestheFill in mainland China has highlighted a significant dispute involving multiple parties, including REGEN Biotech and Aimeike [2][4]. Company Overview - ST Wuzhong's subsidiary, Datuo Medical, received a termination notice from REGEN, which has been acquired by Aimeike, leading to the withdrawal of Datuo Medical's exclusive rights to distribute AestheFill, a popular facial filler in China [2][3]. - AestheFill, developed by REGEN, is a medical aesthetic injection that stimulates collagen regeneration to improve skin tightness and reduce wrinkles [3]. Financial Impact - In 2024, AestheFill's sales in China reached 326 million yuan, accounting for approximately 20% of ST Wuzhong's total revenue [4][6]. - Datuo Medical reported a revenue of 96 million yuan with a gross profit of 37 million yuan, marking its first appearance in ST Wuzhong's significant subsidiaries list [6]. - There is a discrepancy of 230 million yuan between Datuo Medical's reported revenue and AestheFill's sales figures, raising questions about revenue attribution [6]. Legal and Compliance Issues - Aimeike's reasons for terminating the agreement include allegations of Datuo Medical transferring its rights to its parent company, Wuzhong Meixue, and ST Wuzhong's history of financial misconduct leading to regulatory penalties [5][8]. - ST Wuzhong refuted these claims, asserting that no transfer of rights occurred and that the agreement did not stipulate that administrative penalties would trigger termination [5][8]. Market Dynamics - The dispute over AestheFill's distribution rights has not yet significantly impacted the operations of medical aesthetic institutions, which continue to procure the product from Wuzhong Meixue [9][10]. - Concerns remain regarding potential brand and trademark disputes, especially with the recent change in the registration agent for AestheFill [11]. Strategic Importance - For Aimeike, regaining control over AestheFill aligns with its internationalization strategy and aims to enhance its product portfolio, especially as its core product lines face declining growth rates [12][13]. - AestheFill has been approved in 34 countries, positioning it as a competitive product in the global market [14]. Future Outlook - ST Wuzhong has warned investors that the termination of AestheFill's distribution rights could lead to a significant decline in revenue and profits for its medical aesthetics segment in the second half of the year [15]. - Aimeike has indicated that REGEN's new factory in South Korea will ensure a stable supply of AestheFill to meet global demand, including the Chinese market [15].
“姐弟傀儡戏”惹怒证监会!这家医美企业董事长被禁市十年
Nan Fang Du Shi Bao· 2025-07-15 07:32
其中,公司实际控制人、董事长钱群山因组织、指使实施案涉事项,行为恶劣,情节较为严重,证监会 决定对钱群山采取10年证券市场禁入措施。同时,证监会对钱群山给予警告,并处以1500万元罚款。 具体而言,上述"涉嫌信息披露违法违规"包括:未如实披露实际控制人、虚增业绩、关联方非经营性占 用资金情况。记者注意到,在长达5年(2018年—2023年)的时间里,表面是姐姐钱群英作为上市公司 实际控制人,背后则是弟弟钱群山"掌权"、支配控制*ST苏吴。 而在上述5年时间里,这家上市公司连续4年虚增业绩,4年累计虚增营收超17亿元、虚增利润超7000万 元,且存在长期关联方非经营性占用资金情形,截至2023年末,*ST苏吴关联方非经营性占用资金余额 占当期披露净资产的比例高达96.09%。 *ST苏吴董事长钱群山,来源于公司官网 一众高管被罚!董事长被禁市十年 7月14日,*ST苏吴发布公告称,公司收到证监会《行政处罚事先告知书》,公司及其董事长钱群山、 总裁兼董事兼副董事长钱群英、财务总监孙曦、上市公司贸易业务板块子公司总经理骆啸、董事兼审计 委员会委员陈颐一众高管被处罚。 证监会指出,根据当事人违法行为的事实、性质、情节 ...